Home › Compare › HKSHF vs ABBV
HKSHF yields 1.25% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, HKSHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HKSHF + ABBV for your $10,000?
The Hongkong and Shanghai Hotels, Limited, an investment holding company, engages in the ownership, development, and management of hotels, and commercial and residential properties in Asia, the United States, and Europe. It operates through three divisions: Hotels, Commercial Properties, and Clubs and Services. The Hotels division is involved in the operation of hotels; and leasing of commercial shopping arcades and office premises located within the hotel buildings. The Commercial Properties division engages in the development, lease, and sale of residential apartments; and lease of retail and office premises, as well as operation of food and beverage outlets in such premises. The Clubs and Services division operates golf courses, as well as The Peak Tram, a tramway; wholesales and retails food and beverage products; and offers laundry, and management and consultancy services for clubs. The company is also involved in the wholesale and retail of merchandise; provision of dry cleaning, and marketing services; lending and borrowing of funds; and operates golf club and resort, and property investment activities. In addition, it offers tourism, leisure, and other services; and operates Peninsula Boutiques. The company was formerly known as The Hongkong Hotel Company, Limited. The Hongkong and Shanghai Hotels, Limited was incorporated in 1866 and is headquartered in Central, Hong Kong.
Full HKSHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.